Form 4: Intra-Cellular Therapies President Michael Halstead Reports Stock Transactions
SEC Form 4 Filing
Michael Halstead, President of Intra-Cellular Therapies, reports the vesting and settlement of restricted stock units, along with associated tax withholding.
Summary
- On March 1, 2025, Michael Halstead, President of Intra-Cellular Therapies, Inc., reported transactions involving common stock and restricted stock units.
- 12,239 restricted stock units vested and were converted into common stock.
- 6,261 shares were withheld by the issuer to cover tax obligations related to the vesting of these units at a price of $128.2 per share.
- Following these transactions, Halstead directly owns 11,304 shares of common stock and 24,478 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider transactions related to stock-based compensation. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives receiving stock-based compensation. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares upon vesting of the restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Reporting person was granted 36,717 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 03/01/2025 | Date of transaction: vesting of restricted stock units and tax withholding. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.